Clinical trial · Observational
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): This study was terminated by the Sponsor.
Summary
Brief summary (as posted)
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study. The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
Conditions
Conditions (18)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| EGFR Positive Solid Tumor | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
| HER2-positive Breast Cancer | HER2-Positive Breast Carcinoma | ALIAS | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Allogeneic natural killer (NK) cell | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Treatment with Fate Therapeutics' FT500 Cellular Immunotherapy
- description
- Long Term follow-up of subjects who have received an allogeneic, iPSC-derived NK cell in a previous trial.
- interventionNames
- Genetic: Allogeneic natural killer (NK) cell
Primary outcomes (1)
- measure
- Overall Survival (OS) post-Infusion
- timeFrame
- From the date of study entry until the date of documented death due to any cause, assessed up to 60 months.
- description
- OS defined as the interval between the date of the first NK cell infusion and the date of death due to any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study * Subjects who have provided Informed consent prior to their study participation Exclusion Criteria: * Not Applicable
References
Publications (0)
Data not yet available